Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of IMIDomics.

    Client Virtual Booth

    IMIDOMICS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    IMIDomics
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    San Francisco, California
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.imidomics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/imidomics-inc/
    Twitter
    Twitter
    https://twitter.com/IMIDomics

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    UCB announces Strategic Investment in IMIDomics, Inc to Advance Breakthrough Solutions for Immune-Mediated Inflammatory Diseases

    Details:

    The net proceeds will be used to the advancement of novel medicines, including IMB1001, a highly promising humanized antibody targeting CD226, for immune-mediated inflammatory diseases (IMIDs).


    Lead Product(s): IMB1001

    Therapeutic Area: Immunology Product Name: IMB1001

    Highest Development Status: PreclinicalProduct Type: Large molecule

    Partner/Sponsor/Collaborator: UCB Pharma S.A

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Financing March 04, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    IMIDomics Establishes a License and Collaboration Partnership with the University of Barcelona to Advance Treatments for IMIDs

    Details:

    Under this agreement, IMIDomics will leverage UB’s innovative technology and its expertise in areas including biologics discovery as it advances IMB-1003 and IMB-1004 through two research projects aimed at developing new therapeutic approaches.


    Lead Product(s): IMB-1003

    Therapeutic Area: Immunology Product Name: IMB-1003

    Highest Development Status: PreclinicalProduct Type: Large molecule

    Partner/Sponsor/Collaborator: University of Barcelona

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement October 11, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    IMIDomics Announces Strategic Agreement with WuXi Biologics to Advance IMB1001 Antibody Development for Immune-Mediated Inflammatory Diseases

    Details:

    Under the agreement, WuXi will provide comprehensive CMC development and current cGMP manufacturing services for IMIDomics IMB1001, a highly promising humanized antibody targeting CD226, to treat Immune-Mediated Inflammatory Diseases.


    Lead Product(s): TNAX101A

    Therapeutic Area: Immunology Product Name: IMB1001

    Highest Development Status: PreclinicalProduct Type: Large molecule

    Recipient: WuXi Biologics

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement October 04, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    IMIDomics Inc. Secures Exclusive Worldwide Licensing Agreement with TNAX Biopharma Corporation for TNAX101A (IMB1001), A Promising Drug Candidate for Im...

    Details:

    Under this agreement, TNAX is granting IMIDomics the worldwide rights to develop, manufacture, commercialize and sublicense IMB1001 (TNAX101A), a highly promising humanized antibody targeting CD226, a breakthrough target with the potential to treat IMIDs.


    Lead Product(s): TNAX101A

    Therapeutic Area: Immunology Product Name: IMB1001

    Highest Development Status: PreclinicalProduct Type: Large molecule

    Partner/Sponsor/Collaborator: TNAX Biopharma Corporation

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement September 06, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    fermion-oy-2024-05-13

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search